Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

436.40GBp
20 Apr 2018
Change (% chg)

6.00 (+1.39%)
Prev Close
430.40
Open
431.50
Day's High
442.20
Day's Low
429.60
Volume
1,619,590
Avg. Vol
2,115,269
52-wk High
442.20
52-wk Low
246.50

Select another date:

Fri, Apr 20 2018

BRIEF-Indivior Says Filed NDS With Health Canada's For Sublocade Injection

* FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Indivior Says Filed New Drug Submission With Health Canada For Sublocade Injection

* SAYS FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION

BRIEF-Indivior files lawsuits over Suboxone patent

* HAS FILED PATENT LAWSUITS AGAINST DR. REDDY'S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF PATENT RELATING SUBOXONE Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​

* ‍INDIVIOR ENTERS INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR C4X DISCOVERY'S OREXIN-1 (OX1) ANTAGONIST PROGRAM​

Indivior loses another case in battle to protect opioid addiction drug

Shares in Britain's Indivior were hammered on Friday after it lost a second legal case in recent months in its battle to protect the patent of its opioid addiction treatment that generates 80 percent of its revenues.

Indivior to fight U.S. court ruling in favour of competitor drug

LONDON, March 23 Britain's Indivior, the maker of opioid addiction treatment Suboxine Film, said it would fight a U.S. court ruling in favour of would-be generic competitor Alvogen that could pave the way to the launch of a rival to its major product.

BRIEF-Indivior Says ‍U.S. Court Found Alvogen Does Not Infringe Claims Of Certain U.S. Patent​s

* ‍RESPONDS TO COURT RULING IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL

BRIEF-Indivior Says Sublocade Made Available In U.S​

* ‍SUBLOCADE IS NOW AVAILABLE AS FIRST AND ONLY MONTHLY INJECTABLE BUPRENORPHINE IN U.S. TO TREAT PATIENTS WITH MODERATE TO SEVERE OPIOID USE DISORDER​​ Source text for Eikon: Further company coverage:

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

UPDATE 2-Indivior bets on $1 bln anti-addiction shot as legal bill weighs

LONDON, Feb 15 Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

Select another date: